Finance

Beta
Lists
069620:KRX
Daewoong Pharma
â‚©120,900.00
+2.20%
(+2,600.00) 1D
Jun 10, 3:30:05 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 069620...
Open
â‚©117,100
High
â‚©120,900
Low
â‚©117,100
Mkt. cap
1.40T
Avg. vol.
35.10K
Volume
39.25K
Dividend
0.50%
Quarterly dividend
â‚©150
Ex-dividend date
Dec 27, 2023
P/E ratio
6.96
52-wk high
â‚©199,400
52-wk low
â‚©113,700
EPS
â‚©17,369
Shares outstanding
11.59M
No. of employees
2K
Open
â‚©117,100
High
â‚©120,900
Low
â‚©117,100
Mkt. cap
1.40T
Avg. vol.
35.10K
Volume
39.25K
Dividend
0.50%
Quarterly dividend
â‚©150
Ex-dividend date
Dec 27, 2023
P/E ratio
6.96
52-wk high
â‚©199,400
52-wk low
â‚©113,700
EPS
â‚©17,369
Shares outstanding
11.59M
No. of employees
2K
News stories
From sources across the web
Profile
Daewoong Pharmaceutical Co., Ltd. is a pharmaceutical company headquartered in Seoul, South Korea. Daewoong Pharmaceutical primarily engages in the manufacture of pharmaceutical products, including prescription and over-the-counter healthcare products. Wikipedia
About Daewoong Pharma
CEOChang-jae Lee | Seongsoo Park
Employees1.64K
Founded1945
Headquarters-
SectorPharmaceutical industry
Websitedaewoong.com
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
405.45B
411.83B
397.12B
377.80B
Cost of goods sold
190.71B
198.11B
185.96B
196.81B
Cost of revenue
190.71B
198.11B
185.96B
196.81B
Research and development expenses
-10.21B
8.31B
139.98B
44.98B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
163.33B
144.21B
23.12B
107.58B
Operating expense
156.89B
156.83B
169.10B
158.77B
Total operating expenses
347.59B
354.94B
355.06B
355.59B
Operating income
57.86B
56.89B
42.06B
22.21B
Other non operating income
-15.52B
-1.16B
2.77B
-4.61B
EBT including unusual items
43.40B
54.73B
68.97B
33.97B
EBT excluding unusual items
43.40B
54.73B
88.02B
11.82B
Income tax expense
3.28B
7.42B
-16.73B
8.46B
Effective tax rate
7.56%
13.56%
-24.26%
24.89%
Other operating expenses
1.12B
1.17B
1.17B
1.88B
Net income
37.76B
46.37B
89.84B
25.90B
Net profit margin
9.31%
11.26%
22.62%
6.86%
Earnings per share
-
-
-
-
Interest and investment income
599.36M
-
1.12B
618.34M
Interest expense
-3.11B
-
-3.53B
-2.75B
Net interest expenses
-2.51B
-
-2.41B
-2.13B
Depreciation and amortization charges
1.24B
1.77B
1.43B
1.15B
EBITDA
70.15B
69.45B
56.04B
38.38B
Gain or loss from assets sale
10.42M
-12.80M
-52.31B
35.01M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer